XNYS · Healthcare · Drug Manufacturers - General
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, antiviral, and vaccines, and has been growing its presence in oncology and immunology, as well. GSK uses joint ventures to gain additional scale in certain markets like HIV.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-04-29 | Q1 2026 | 1.17 | 1.25 | +6.84% | $10.30B | ✅ Beat | +1.06% | -1.69% | -1.67% |
| 2026-02-04 | Q4 2025 | 0.64 | 0.68 | +6.25% | $11.46B | ✅ Beat | +1.41% | +2.20% | -4.75% |
| 2025-10-29 |
| Q3 2025 |
| 1.26 |
| 1.48 |
| +17.78% |
| $11.53B |
| ✅ Beat |
| — |
| — |
| — |
| 2025-07-30 | Q2 2025 | 1.12 | 1.24 | — | $10.66B | ✅ Beat | — | — | — |
| 2025-04-30 | Q1 2025 | 1.04 | 1.13 | +8.65% | $9.46B | ✅ Beat | -2.76% | -6.73% | +2.96% |
| 2025-02-05 | Q4 2024 | 0.43 | 0.58 | +34.88% | $10.06B | ✅ Beat | -3.50% | -4.16% | +6.23% |
| 2024-10-30 | Q3 2024 | 1.23 | 1.29 | +4.88% | $10.42B | ✅ Beat | -0.68% | -3.00% | -7.78% |
| 2024-07-31 | Q2 2024 | 0.99 | 1.10 | +11.11% | $9.95B | ✅ Beat | +2.24% | +1.55% | +13.26% |
Showing last 8 quarters.